QCG
STOK icon

Quadrant Capital Group’s Stoke Therapeutics STOK Stock Holding History

Quadrant Capital Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-221
Closed -$871 – 2778
2023
Q3 		$871 Sell
221
-1,224
-85% -$8.05K ﹤0.01% 2506
2023
Q2 		$15.4K Hold
1,445
– – ﹤0.01% 1831
2023
Q1 		$12K Buy
1,445
+1,079
+295% +$9.73K ﹤0.01% 1944
2022
Q4 		$3.38K Buy
+366
New +$3.81K ﹤0.01% 2294
2022
Q2 		– Sell
-113
Closed -$2K – 2726
2022
Q1 		$2K Buy
+113
New +$2.26K ﹤0.01% 2195

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quadrant Capital Group's STOK Position: Q4 2023 in Review

Quadrant Capital Group sold out of Stoke Therapeutics (STOK) in Q4 2023, closing a stake of 221 shares — an estimated $871 sold.

Quadrant Capital Group first reported a position in STOK in Q1 2022 and held it in 5 quarters. The position peaked at $15.4K in Q2 2023. 81 funds tracked by Wall St. Rank hold STOK as of Q4 2023.

  • Quadrant Capital Group reported no remaining Stoke Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 221 Stoke Therapeutics shares in Q4 2023, an estimated $871.
  • Quadrant Capital Group first reported a position in Stoke Therapeutics in Q1 2022 and held it in 5 quarters.
  • Quadrant Capital Group's Stoke Therapeutics position peaked at $15.4K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.